A clinical system—not a testing menu.
Longevity diagnostics begin with the person. Medical and family history, current symptoms, medications, prior results, sleep, nutrition, movement, stress, travel and personal goals establish the context for every measurement. A physical examination and age- and risk-appropriate preventive care remain foundational.
Depending on clinical need, testing may include a standard laboratory foundation plus selected cardiometabolic, inflammatory, endocrine, nutrient and organ-function markers. Body composition, blood pressure, strength, aerobic capacity, recovery, sleep and cognition can add a functional view. Specialized studies are considered when the history and the likelihood of changing care justify them.
What biological age can—and cannot—say.
Biological age is not one universal measurement. Different models may use blood biomarkers, DNA methylation, physical performance or combinations of variables, so two methods can produce different estimates for the same person. Each estimate reflects the inputs and assumptions of that specific method.
A biological age result should never be presented as a diagnosis, a guaranteed forecast of lifespan or proof that a treatment worked. Its most responsible use is as one signal within a larger picture that includes established risk factors, symptoms, examination, conventional screening and outcomes that matter to daily life.
Why the trajectory matters.
A single result is a snapshot. Repeated measurements can reveal direction, but only when the testing method and collection conditions are sufficiently comparable. Acute illness, fasting status, training load, sleep, medication changes and laboratory variation can all influence a value.
Longitudinal review asks three questions: Is the change reliable? Is it clinically meaningful? Does it alter a decision that improves health, function or safety? This approach keeps attention on outcomes rather than chasing every fluctuation.
A two-layer biological aging assessment.
Clinical PhenoAge is the core. When albumin, creatinine, glucose, C-reactive protein, alkaline phosphatase and the required blood-count measures are available, the program can calculate a transparent, repeatable estimate of phenotypic aging. It is a research-based model—not a diagnosis or an individual lifespan forecast.
DunedinPACE is the optional advanced layer. This DNA-methylation measure estimates the pace at which aging-related change is occurring. It does not assign a literal cellular age, and a change in the result does not by itself establish that a treatment caused an improvement.
WellSkor AI is being developed to organize these results with laboratory measurements, personal context and change over time into a shared view for patient and physician. It does not independently diagnose disease, prescribe treatment or validate a result. Dr. Hall’s clinical review determines what deserves attention, whether additional evaluation is appropriate and when reassessment may be useful.